Analyst firms · Barclays · TEVA

Barclays TEVA price target and rating history

Teva Pharmaceutical Industries Limited (TEVA) · Health Care

Barclays rates Teva Pharmaceutical Industries Limited (TEVA) Overweight with a $35 price target, as of its latest action on Dec 9, 2025. It has published 3 rating actions on TEVA since February 2022, including 1 upgrade and 0 downgrades. Across 6 firms with a TEVA price target in the last 12 months, the median target is $47.50. Barclays's $35 is 26% below that.

Current rating
Overweight
Price target
$35
Median target, all firms
$47.50
Actions on TEVA
3

Barclays price target on TEVA

$35$23$112023202420252026
Barclays price target on TEVA, each point a stated target, February 2022 to December 2025.

Every Barclays rating on TEVA

How other firms rate TEVA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightBuy$52Nov 2, 2026
TD CowenBuy$55Oct 1, 2026
OppenheimerOutperform$50Sep 23, 2026
Leerink PartnersOutperform$45Sep 9, 2026
BarclaysOverweight$35Dec 9, 2025
ScotiabankSector Outperform$35Dec 5, 2025

Questions about Barclays and TEVA

What is Barclays's price target for TEVA?
Barclays's latest stated price target for Teva Pharmaceutical Industries Limited (TEVA) is $35, from its action on Dec 9, 2025.
What is Barclays's rating on TEVA?
Barclays rates TEVA Overweight, a bullish rating, as of Dec 9, 2025.
When did Barclays last change its view on TEVA?
On Dec 9, 2025, Barclays starts coverage at Overweight, price target $35.
How does Barclays's TEVA target compare with other analysts?
Across 6 firms with a TEVA price target in the last 12 months, the median target is $47.50. Barclays's $35 is 26% below that.

More TEVA rating histories

All Barclays ratingsTEVA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.